Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00286442 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus

A Phase 3 study of Diabetes Mellitus, sponsored by Takeda.

Completed
Registry status
Phase 3
Development phase
527
Enrollment target
20
Study locations

NCT00286442 is a Phase 3 study of Diabetes Mellitus that has completed, run by Takeda. The registered enrollment target is 527 participants, below the 1,865-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00286442, a Phase 3 study of Diabetes Mellitus, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 3
Development phase
527 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with metformin in adults with type 2 diabetes mellitus.

Conditions Studied

Interventions

  • DRUG Metformin
  • DRUG Alogliptin and metformin

Study Locations (20)

California

  • - Anaheim
  • - Artesia
  • - Fresno
  • - Los Angeles
  • - Mission Viejo
  • - Northridge
  • - Orange
  • - San Diego
  • - Walnut Creek

Florida

  • - Cocoa Beach
  • - Longwood
  • - Ocala
  • - Ocoee
  • - Saint Cloud

Indiana

  • - Avon
  • - Elkhart

Arizona

  • - Phoenix

Colorado

  • - Denver

District of Columbia

  • - Washington D.C.

Hawaii

  • - Honolulu

Trial Details

FieldValue
Enrollment Target 527 participants
Start Date 2006-03
Est. Completion 2007-06
Phase Phase 3

Sponsor

Takeda

408 total trials

What the Registry Record Tells You About NCT00286442

The ClinicalTrials.gov registry entry for NCT00286442 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 527 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,865-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (72% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Metformin is the first listed.

NCT00286442 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Indiana.

Frequently Asked Questions

What is clinical trial NCT00286442 about?

NCT00286442 is a clinical study titled "Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with metformin in adults with type 2 diabetes mellitus.

What is the current status of trial NCT00286442?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 527 participants. The study started on 2006-03. Estimated completion is 2007-06.

What conditions does trial NCT00286442 study?

This clinical trial studies the following conditions: Diabetes Mellitus.

What interventions are being tested in trial NCT00286442?

The interventions under investigation include: Metformin (DRUG), Alogliptin and metformin (DRUG).

Who is sponsoring clinical trial NCT00286442?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00286442 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.